Phaseline

Companies › Philogen

Philogen: clinical trials, targets and expected readouts

8 active drug programs in 21 registered trials: 12 Phase 2, 6 Phase 1, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Daromun
TNF-alpha-based immunotherapy
–Phase 3Melanoma Stage IIIBDec 2027
L19IL2
Fibronectin binding agent
FN1Phase 3Malignant Melanoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma …May 2028
L19TNF
L19-targeting TNF fusion protein
TNFPhase 3Malignant Melanoma; Glioblastoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma …Jul 2028
Onfekafusp alfa–Phase 2Soft Tissue Sarcoma; GlioblastomaDec 2026
IL12-L19L19
Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin
IL12A, IL12B, FN1Phase 1Advanced Solid TumorDec 2026
[177Lu]Lu-OncoFAP-23
Radioligand targeting fibroblast activation protein (FAP)
FAPPhase 1FAPMay 2028
F8IL10
Engineered human interleukin-10 fused to F8 antibody fragment targeting fibronectin
IL10Phase 1Rheumatoid Arthritis (RA)Sep 2028
[68Ga]Ga-OncoACP3
Gallium-68 labelled prostate cancer imaging agent
–Phase 1Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04733183Onfekafusp alfaPhase 2Soft Tissue SarcomaOncologyDec 2025
NCT06336291L19TNFPhase 2GlioblastomaOncologyJun 2026
NCT07600554[68Ga]Ga-OncoACP3Phase 1Prostate CancerOncologyOct 2026
NCT04443010Onfekafusp alfaPhase 1GlioblastomaOncologyDec 2026
NCT04471987IL12-L19L19Phase 1Advanced Solid TumorOncologyDec 2026
NCT03567889DaromunPhase 3Melanoma Stage IIIBOncologyDec 2027
NCT06640413L19IL2Phase 1FAPOncologyMay 2028
NCT06640413[177Lu]Lu-OncoFAP-23Phase 1FAPOncologyMay 2028
NCT06284590L19IL2Phase 2Melanoma Stage IIIOncologyJul 2028
NCT06284590L19IL2Phase 2Melanoma Stage IIIOncologyJul 2028
NCT06284590L19TNFPhase 2Melanoma Stage IIIOncologyJul 2028
NCT07245992F8IL10Phase 1Rheumatoid Arthritis (RA)ImmunologySep 2028
NCT02938299L19IL2Phase 3Malignant MelanomaOncologyDec 2028
NCT02938299L19TNFPhase 3Malignant MelanomaOncologyDec 2028
NCT07227870L19IL2Phase 2Locally Advanced Basal Cell CarcinomaOncologyFeb 2031
NCT07227350L19IL2Phase 2Locally Advanced Basal Cell CarcinomaOncologyFeb 2031
NCT07227350L19IL2Phase 2Locally Advanced Basal Cell CarcinomaOncologyFeb 2031
NCT07228442L19IL2Phase 2Locally Advanced Cutaneous Squamous Cell CarcinomaOncologyFeb 2031
NCT07227870L19TNFPhase 2Locally Advanced Basal Cell CarcinomaOncologyFeb 2031
NCT07228442L19TNFPhase 2Locally Advanced Cutaneous Squamous Cell CarcinomaOncologyFeb 2031
NCT07227350L19TNFPhase 2Locally Advanced Basal Cell CarcinomaOncologyFeb 2031

Targets

FN1 (2) TNF (1) IL12A (1) IL12B (1) FAP (1) IL10 (1)

Companies with the same targets

Johnson & Johnson (Janssen) Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Chia Tai Tianqing Pharmaceutical Group Prestige Biopharma Kahr Medical Taizhou Mabtech Pharmaceutical Chiesi Farmaceutici Teva Branded Pharmaceutical Products R&D

Companies built like this

Lantheus Medical Imaging Chengdu New Radiomedicine Technology Stemline Therapeutics Minghui Pharmaceutical (Hangzhou) Pierre Fabre Medicament

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.